Sarepta Therapeutics Names Art Krieg, M.D., Chief Scientific Officer

  Sarepta Therapeutics Names Art Krieg, M.D., Chief Scientific Officer

Business Wire

CAMBRIDGE, Mass. -- January 9, 2014

Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based
therapeutics, today announced Arthur "Art" Krieg, M.D., has been named senior
vice president and chief scientific officer. In this role, Dr. Krieg will lead
the company’s drug discovery and early-stage research activities.

“We are excited to welcome Art to Sarepta as we advance the field of RNA
medicine with our proprietary technologies,” said Chris Garabedian, president
and chief executive officer of Sarepta Therapeutics. “With more than two
decades of experience in oligonucleotide drug development, Art’s outstanding
scientific leadership will support the advancement of our exon skipping
franchise in Duchenne muscular dystrophy as well as the expansion of our
product pipeline.”

Dr. Krieg joins Sarepta from RaNA Therapeutics, where he served as chief
executive officer since he co-founded the company in 2011. Prior to RaNA, he
was chief scientific officer of Pfizer’s Oligonucleotide Therapeutics Unit
from 2008 to 2011. Previously, he was the chief scientific officer, executive
vice president of research and development, and co-founder of Coley
Pharmaceutical Group, prior to its acquisition by Pfizer in 2008.

Dr. Krieg discovered the immune stimulatory CpG DNA motif in 1994, which led
to a new approach to immunotherapy and vaccine adjuvants. Based on this
technology, he co-founded Coley Pharmaceutical Group in 1997, discovering and
taking four novel oligonucleotides into clinical development. He was a
co-founder of the first antisense journal, Oligonucleotides, which he edited
for 16 years, and he co-founded the Oligonucleotide Therapeutic Society. He is
a director of Cytos Biotechnology and a member of the scientific advisory
boards of RaNA and Mirna Therapeutics. Dr. Krieg received his doctor of
medicine degree from Washington University, completed a residency in internal
medicine at the University of Minnesota and a rheumatology fellowship at the
National Institutes of Health. Upon completing his medical training, he joined
the University of Iowa, becoming professor of internal medicine in the
Division of Rheumatology. He has published more than 240 scientific papers and
is co-inventor on 47 issued U.S. patents covering oligonucleotide
technologies.

“The recent resurgence in the field of RNA therapeutics has been due in part
to the excitement around Sarepta’s exon skipping therapies and their potential
for patients with Duchenne,” said Dr. Krieg. “I look forward to joining the
Sarepta team as we seek to advance these programs and realize the full
potential of Sarepta’s technologies to address other serious and
life-threatening diseases.”

In connection with Dr. Krieg’s hire, the Compensation Committee of the Board
of Directors of Sarepta approved an inducement stock option grant to Dr. Krieg
under Nasdaq Listing Rule 5635(c)(4), with a grant date of January 13, 2014,
of an option to purchase 275,000 shares of the Company’s common stock with an
exercise price equal to the last reported sale price of the Company’s common
stock on January 13, 2014. One-fourth of the shares underlying Dr.Krieg’s
option will vest on January13, 2015 and thereafter 1/48th of the shares
underlying Dr. Krieg’s option will vest monthly, such that the shares
underlying the option will be fully vested on January13, 2018, in each case,
subject to Dr.Krieg’s employment with Sarepta on such vesting dates.

About Sarepta Therapeutics

Sarepta Therapeutics is focused on developing first-in-class RNA-based
therapeutics to improve and save the lives of people affected by serious and
life-threatening rare and infectious diseases. The Company's diverse pipeline
includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well
as potential treatments for some of the world's most lethal infectious
diseases. Sarepta aims to build a leading, independent biotech company
dedicated to translating its RNA-based science into transformational
therapeutics for patients who face significant unmet medical needs. For more
information, please visit us at www.sarepta.com.

Forward-Looking Statements and Information

This press release contains forward-looking statements. These forward-looking
statements generally can be identified by use of words such as "believes or
belief," "anticipates," "plans," "expects," "will," "intends," "potential,"
"possible," "advance" and similar expressions. These forward-looking
statements include statements about the development of our Duchenne muscular
dystrophy platform, our product pipeline based on RNA technologies and
management contributions towards the same.

Each forward-looking statement contained in this press release is subject to
risks and uncertainties that could cause actual results to differ materially
from those expressed or implied by such statement. Applicable risks and
uncertainties include, among others: Any of Sarepta's drug candidates,
including eteplirsen, may fail in development, may not receive required
regulatory approvals (including Subpart H accelerated approval), or may not
become commercially viable within expected time frames or at all due to delays
or other reasons; and those risks identified under the heading "Risk Factors"
in Sarepta's Annual Report on Form 10-K for the full year ended December 31,
2012 and as updated by our 2013 third quarter 10-Q, and filed with the
Securities and Exchange Commission (SEC).

Any of the foregoing risks could materially and adversely affect Sarepta's
business, results of operations and the trading price of Sarepta's common
stock. For a detailed description of risks and uncertainties Sarepta faces,
you are encouraged to review the Company's filings with the SEC. We caution
investors not to place considerable reliance on the forward-looking statements
contained in this press release. Sarepta does not undertake any obligation to
publicly update its forward-looking statements based on events or
circumstances after the date hereof.

Contact:

Sarepta Investor Contact:
Erin Cox, 857-242-3714
ecox@sarepta.com
or
Sarepta Media Contact:
Jim Baker, 857-242-3710
jbaker@sarepta.com
 
Press spacebar to pause and continue. Press esc to stop.